Â© Reuters. FILE PHOTO: The logo of Swiss drug maker Novartis is seen at the company’s plant in Stein, northern Switzerland, October 23, 2017. REUTERS / Arnd Wiegmann / File Photo
(Reuters) – Healthcare investment firm Syncona Ltd on Wednesday announced that Novartis AG will purchase its Gyroscope Therapeutics unit for up to $ 1.5 billion as the Swiss drug maker seeks access to British society’s gene therapy for a disease causing blindness.
Fusion media or anyone involved with Fusion Media will not accept any responsibility for any loss or damage resulting from reliance on any information, including data, quotes, graphics and buy / sell signals contained in this website. Please be fully informed about the risks and costs associated with trading in the financial markets, it is one of the riskiest forms of investing possible.